Innovative Imaging Technique Bridges Whole-Body and Cellular Cancer Scans

A pioneering imaging technology developed by researchers in Scotland is poised to revolutionize cancer study by linking whole-body cancer scans with detailed cellular imaging. This novel method could illuminate the diverse characteristics of tumors that influence their growth and response to treatment.

Traditional medical scans can identify the locations of tumors within the body, but they fall short of revealing the intricate activities of individual cells within each tumor. On the other hand, microscopy offers detailed insights at the cellular level but lacks the ability to portray the broader behavior of cancer across the entire body. Researchers at the University of Glasgow have successfully integrated these two perspectives into a solitary imaging system.

By merging positron emission tomography (PET) scans with bioluminescence and fluorescence techniques, the system provides a comprehensive view: it locates tumors, identifies significant lesions, and subsequently allows for an in-depth examination of those tumors, including their surrounding cells and tissues.

Professor David Lewis, leading the study at the Cancer Research UK Scotland Institute and the University of Glasgow, stated: “This exciting technology allows us to build a clearer map of how cancer behaves at both a holistic and microscopic level. It allows researchers to follow tumors in the body, identify the lesions that matter, and then zoom in to study those cancer cells and their environment, giving us new information about cancer, which we can take forward into better and more precise treatments.”

Annually, more than 403,000 individuals are diagnosed with cancer in the UK, including over 34,800 in Scotland alone. The disease claims the lives of approximately 170,000 people across the UK each year, with 16,400 in Scotland, highlighting the urgent need for innovative approaches to improving cancer research and treatment.

This new method, still in preclinical trials using mice, connects large-scale imaging with detailed cellular analysis. It offers a promising avenue for comprehending why different tumors demonstrate varied behaviors and responses to therapies. By allowing researchers to label and track cancer cells, it highlights the interactions of tumor cells with their surroundings, such as immune cells and blood vessels, which can significantly impact cancer progression and treatment outcomes.

Though currently not applicable to human patients, this method is expected to enhance preclinical testing by allowing researchers to study each tumor's unique biology. Its applicability was demonstrated in liver and lung cancer models, and it holds potential for expanding research across various disciplines, including oncology, immunology, neuroscience, and regenerative medicine.